The Vatican has launched a meticulous three-month restoration of Michelangelo's iconic 'Last Judgment' fresco in the Sistine Chapel, aiming to revive the masterpiece's original chromatic brilliance obscured by decades of grime.
A highly sensitive whistleblower complaint alleging misconduct by Director of National Intelligence Tulsi Gabbard has been locked within the intelligence bureaucracy since May, with Congress aware of its existence but blocked from reviewing it amid accusations of obstruction.
Canadian junior miner G2 Goldfields Inc. (TSX: GTWO), despite recent losses, is projected by analysts to reach profitability within two years, backed by aggressive growth forecasts and a debt-free balance sheet.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Digital infrastructure firm IREN secures a landmark $9.7 billion agreement with Microsoft and a massive GPU procurement from Dell, marking a strategic shift from cryptocurrency mining to powering the AI cloud boom.
Alibaba Group is making a major strategic push into artificial intelligence, launching a proprietary AI chip to challenge Nvidia, upgrading its Qwen models, and planning a massive marketing campaign for its AI app during the Lunar New Year holiday.
Amid a quarter dominated by mega-cap tech and AI fervor, Pzena Investment Management's value-focused fund highlighted discount retailer Dollar General as a key performer, driven by strong earnings that propelled its stock.
Fidelity Investments and Broadcom have settled a legal dispute that threatened Fidelity's access to business-critical software, averting a potential operational crisis. The agreement, reached just before a key court hearing, ensures continued service for a Fidelity subsidiary.
Israeli police have detained municipal officials and business figures suspected of embezzling millions in international donations intended for communities devastated by the October 7 Hamas attacks, launching a major fraud investigation.
Taiwan Semiconductor Manufacturing Co. (TSMC) has unveiled an aggressive capital expenditure plan for 2026, signaling robust confidence in sustained demand driven by artificial intelligence and high-performance computing, which has spurred a significant rally in its shares and upward revisions from analysts.
Investment firm Curreen Capital posted a 30.97% annual return for 2025, crediting its focus on undervalued, well-managed companies. The firm's latest investor letter highlights home service provider Frontdoor (FTDR) as a key holding, despite it not being among the most popular hedge fund picks.
Founder Scott Davies steps into executive chairman role as the Welsh honey maker rebrands to Hilltop Food Group and targets doubling turnover within five years through international expansion and new product categories.
New home listings in the San Antonio metro area fell sharply in December, the steepest decline among major U.S. cities, as a growing imbalance between sellers and buyers prompts homeowners to stay put.
Brand incubator Maesa is betting on the growing body care category with the launch of Ontu, a new line bringing high-performance, facial-inspired formulas to Target shelves at accessible price points, capitalizing on shifting consumer skincare rituals.
In a strategic pivot, Tesla's Q4 earnings call revealed plans to halt Model S and X production at its Fremont plant, repurposing the space for a massive push into humanoid robotics with the Optimus project, as Elon Musk outlines a vision for a million-unit annual output.
